Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22569804 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Cancer;   Pancreatic Cancer
Interventions: Drug: IMMU-107;   Drug: placebo;   Drug: Gemcitabine

Indicates status has not been verified in more than two years